News for Celldex Therapeutics, Inc. (CLDX)

HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (CLDX) today announced that Denice M. Torres has been elected to the company's Boa

Revenue: $0.7 million for Q1 2025, falling short of the estimated $1.05 million.Earnings Per Share (EPS): Reported at ($0.81), missing the estimated EPS of ($0

On May 9, 2025, UBS analyst Trung Huynh released a report on Celldex Therapeutics (CLDX), maintaining a "Buy" rating but lowering the price target from $44.00 t

We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take a look at where Celldex Therapeutics, Inc. (NASDAQ:CLDX) stands against other best cancer stocks to invest in for long-term gain. Surging Cancer Cases and Costs Drive Growth in the Global Oncology […]

We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take a look at where Celldex Therapeutics, Inc.

On May 9, 2025, HC Wainwright & Co.'s analyst Joseph Pantginis issued an update on Celldex Therapeutics (CLDX), maintaining a 'Buy' rating on the stock. The fir

Robust pipeline with potential in multiple severe inflammatory and autoimmune diseases.Increased R&D investment to drive future growth, despite short-term fina

Strong execution and progress across pipeline with multiple key data read outs expected in 2025Late breaking oral presentation on Phase 2 CSU program at EAACI 2

On May 6, 2025, Celldex Therapeutics (CLDX) received reaffirmation from HC Wainwright & Co., with analyst Joseph Pantginis reiterating a 'Buy' rating on the sto

Celldex (CLDX) has shared promising histology data from its Phase 2 trial of barzolvolimab for treating eosinophilic esophagitis (EoE). Initial biopsies reveale

Phase 2 study fully enrolled; data expected in 2H 2025 HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiation...

Morgan Stanley backs Celldex Therapeutics for growth with barzolvolimab's market-leading potential in chronic urticaria. Read more here.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Celldex Therapeutics Inc (CLDX), a clinical-stage biotechnology company, announced on March 4, 2025, that its management will participate in fireside chats at t

HAMPTON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (CLDX) announced today that management will participate in fireside chats at two

Summary Celldex Therapeutics Inc (CLDX) announced on March 1, 2025, promising results from its Phase 2 studies of barzolvolimab, a humanized monoclonal antibody

- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU -- 82% of CSU patients reported that symptoms no longer had

Strengths: Innovative immunotherapy technologies and a robust pipeline targeting severe diseases.Weaknesses: High research and development costs with no produc